This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original) Compounds of the general formula (I):



in which:

X = O or S;

R1 is chosen from:

- Alk-COOH,
- Alk-C(=O)-$(O)_m$-Ar,
- Alk-C(=O)-$(O)_m$-Het,
- Alk-C(=O)-$(O)_m$-Alk,
- Alk-C(=O)-$(O)_m$-cycloalkyl,
- Alk-C(=O)NRR',
- Alk-$(O)_m$-Ar,
- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

R2 is chosen from -Alk, -Ar and -cycloalkyl;

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, -CF_3, -NRR' and -NO_2;

in which, in the definitions of R1-R6:

each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -COOH, -NRR', $-C(=O)-(O)_mAlk$, -Het and $-NO_2$;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -AlkAr, -COOH, $-C(=O)-(O)_mAlk$, $-Alk-C(=O)-(O)_m-Alk$, -NRR', -Het, $-NO_2$, $-S(O)_nAr$ and $-S(O)_nAlk$;

R and R' are chosen independently from H and Alk;

m = 0 or 1;

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts,

with the exception of the compounds for which:

1) R1 = $-CH_2-C(=O)Me$, R2 = -Me, X = O, R3, R5 = H and each R4, R6 = H or OMe.

Claim 2. (Original) Compounds of the formula (I) according to Claim 1, in which:

X = O or S;

R1 is chosen from:

- Alk-COOH,
- $Alk-C(=O)-(O)_m-Ar$,
- $Alk-C(=O)-(O)_m-Het$,
- $Alk-C(=O)-(O)_m-Alk$,
- $Alk-C(=O)-(O)_m$-cycloalkyl,
- Alk-C(=O)NRR',
- $Alk-(O)_m-Ar$,
- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

R2 represents -Ar or -cycloalkyl;

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' and $-NO_2$;

in which, in the definitions of R1-R6:

each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -COOH, -NRR', $-C(=O)-(O)_mAlk$, -Het and $-NO_2$;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -AlkAr, -COOH, $-C(=O)-(O)_mAlk$, $-Alk-C(=O)-(O)_m-Alk$, -NRR', -Het, $-NO_2$, $-S(O)_nAr$ and $-S(O)_nAlk$;

R and R' are chosen independently from H and Alk;

m = 0 or 1,

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts.

Claim 3. (Original) Compounds of the formula (I) according to Claim 1, in which:

X = S;

R1 is chosen from:

- Alk-COOH,
- $Alk-C(=O)-(O)_m-Ar$,
- $Alk-C(=O)-(O)_m-Het$,
- $Alk-C(=O)-(O)_m-Alk$,
- $Alk-C(=O)-(O)_m-cycloalkyl$,
- Alk-C(=O)NRR',
- $Alk-(O)_m-Ar$,
- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

R2 is chosen from -Alk, -Ar and -cycloalkyl;

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' and $-NO_2$;

in which, in the definitions of R1-R6:

each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -COOH, -NRR', $-C(=O)-(O)_mAlk$, -Het and $-NO_2$;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -AlkAr, -COOH, $-C(=O)-(O)_mAlk$, $-Alk-C(=O)-(O)_m-Alk$, -NRR', -Het, $-NO_2$, $-S(O)_nAr$ and $-S(O)_nAlk$;

R and R' are chosen independently from H and Alk;

m = 0 or 1;

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts.

Claim 4. **(Previously Presented)** Compounds of the formula (I) according to claim 1, in which R3, R4, R5, R6 = H.

Claim 5. **(Previously Presented)** Compounds of the formula (I) according to claim 1, in which X = S.

Claim 6. **(Previously Presented)** Compounds of the formula (I) according to claim 1, in which R2 = Ar optionally substituted by -CN or -COOH, or alkyl optionally substituted by -COOH.

Claim 7. **(Previously Presented)** Compounds of the formula (I) according to claim 1, in which R2 = phenyl optionally substituted by -CN or -COOH.

Claim 8. **(Previously Presented)** Compounds of the formula (I) according to claim 1, in which R2 = phenyl substituted by -CN.

Claim 9. **(Previously Presented)** Compounds of the formula (I) according to claim 1, in which m = 0.

Claim 10. **(Previously Presented)** Compounds of the formula (I) according to claim 1, in which R1 = $-CH_2-COOH$, $-CH_2-C(=O)-(O)_m-Ar$, $-CH_2-C(=O)-(O)_m-Het$, $-CH_2-C(=O)-(O)_m-Alk$, $-CH_2-C(=O)NRR'$, $-CH_2-(O)_m-Ar$, $-CH_2-O-Alk$, $-CH_2-O-Alk-Ar$ or $-CH_2-O-Het$, in which

Ar is optionally substituted by one or more groups chosen from Hal, -OAlk, -Ar, -Alk, $-O-Alk-Ar$, $-C(=O)-(O)_m-Alk$, $-Alk-C(=O)-(O)_mAlk$, $-S(O)_n-Ar$, $-S(O)_n-Alk$, $-O-CF_3$, -CN and -OH,

in which m = 0 or 1, n = 2.

Claim 11. **(Previously Presented)** Compounds of the formula (I) according to claim 1, in which R1 = $-CH_2-C(=O)-Ar$, $-CH_2-C(=O)-Alk$ or $-(CH_2)_m'-(O)_m-Ar$, in which

Ar is optionally substituted by one or more groups chosen from Hal, -OAlk, -Ar, -Alk, $O-Alk-Ar$, $-C(=O)-(O)_m-Alk$, $-Alk-C(=O)-(O)_mAlk$, $-S(O)_n-Ar$, $-S(O)_n-Alk$, $-O-CF_3$, -CN and -OH,

in which m = 0 or 1, m' = 1 or 2, n = 2.

Claim 12. **(Previously Presented)** Compounds of the formula (I) according to claim 1, in which m' = 2 if m = 1.

Claim 13. **(Previously Presented)** Compounds of the formula (I) according to claim 1, in which R1 = $-CH_2-C(=O)-Alk$.

Claim 14. **(Original)** Compounds of the formula (I) according to Claim 13, in which Alk = $-CMe_3$.

Claim 15. **(Previously Presented)** Compounds of the formula (I) according to claim 1, in which Ar = phenyl.

Claim 16. (Previously Presented) Compounds of the formula (I) according to claim 1, in which R1 = -CH_2-C(=O)-phenyl or -CH_2-phenyl in which phenyl is optionally substituted by one or more groups chosen from -Hal, -OAlk, -CN, -SO_2-Alk and -Alk.

Claim 17. (Previously Presented) Compounds of the formula (I) according to claim 1, chosen from:

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-chlorophenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-phenylethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2-methoxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-biphenyl-4-ylethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-*p*-tolylethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-methoxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-fluorophenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(3-methoxyphenyl)ethanone;

methyl 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-3-methoxypropionate;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2-benzyloxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-benzyloxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(3,4-dimethoxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-phenylpropan-1-one;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2,4-dimethoxyphenyl)ethanone;

1-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-3,3-dimethylbutan-2-one;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-naphthalen-2-ylethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2,3-dichloro-4-methoxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-benzyloxy-3-methoxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2-benzyloxy-5-fluorophenyl)ethanone;

(3-hydroxybenzo[*b*]thiophen-2-yl)phenylmethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)acetamide;

{3-[2-(4-fluorophenoxy)ethoxy]benzo[*b*]thiophen-2-yl}phenylmethanone;

(3-phenethyloxybenzo[*b*]thiophen-2-yl)phenylmethanone;

methyl 3-{4-[2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)ethoxy]phenyl}propionate;

{3-[2-(naphthalen-1-yloxy)ethoxy]benzo[*b*]thiophen-2-yl}phenylmethanone;

{3-[2-(2-methoxyphenoxy)ethoxy]benzo[*b*]thiophen-2-yl}phenylmethanone;

1-{4-[2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)ethyl]phenyl}ethanone;

ethyl 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-4-phenylbutyrate;

[3-(3-phenoxypropoxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

[3-(4-*tert*-butylbenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

[3-(2-benzenesulfonylmethylbenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

methyl 4-(2-benzoylbenzo[*b*]thiophen-3-yloxymethyl)benzoate;

phenyl[3-(4-trifluoromethoxybenzyloxy)benzo[*b*]thiophen-2-yl]methanone;

[3-(biphenyl-2-ylmethoxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

[3-(4-methylbenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

(3-benzyloxybenzo[*b*]thiophen-2-yl)phenylmethanone;

[3-(2,3-difluorobenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

sodium 2-(4-cyanobenzoyl)benzo[b]thiophen-3-olate;

4-[3-(2-chloro-4-fluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3,4-dichlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2-cyanobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3-cyanobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-cyanobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3,5-bis-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

methyl 4-[2-(4-cyanobenzoyl)benzo[b]thiophen-3-yloxymethyl]benzoate;

4-[3-(4-fluoro-2-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-(3-pentafluorophenylmethoxybenzo[*b*]thiophene-2-carbonyl)benzonitrile;

4-[3-(2,6-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2-chlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(biphenyl-2-ylmethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-bromo-2-fluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2-methylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2,6-dichlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3-chlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2-bromobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-bromobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-(3-benzyloxybenzo[*b*]thiophene-2-carbonyl)benzonitrile;

4-[3-(3-bromobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2,5-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3,4-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3,5-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2,4-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2,3-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-methanesulfonylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-iodobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-{3-[2-(4-chlorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-[3-(2-oxo-2-phenylethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-{3-[2-(2-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-[3-(2-biphenyl-4-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2-oxo-2-*p*-tolylethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-{3-[2-(4-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-[3-(2-adamantan-1-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-{3-[2-(4-fluorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-{3-[2-(3-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-{3-[2-(2-benzyloxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-{3-[2-(4-benzyloxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-{3-[2-(3,4-dimethoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-{3-[2-(2,4-dimethoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-[3-(2-naphthalen-2-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-{3-[2-(4-benzyloxy-3-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}-benzonitrile;

4-{3-[2-(2-benzyloxy-5-fluorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}-benzonitrile;

(3-hydroxybenzofuran-2-yl)phenylmethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(4-chlorophenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(2-methoxyphenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-biphenyl-4-ylethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-*p*-tolylethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(4-methoxyphenyl)ethanone;

1-adamantan-1-yl-2-(2-benzoylbenzofuran-3-yloxy)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(4-fluorophenyl)ethanone;

methyl 2-(2-benzoylbenzofuran-3-yloxy)-3-methoxypropionate;

2-(2-benzoylbenzofuran-3-yloxy)-1-(2-benzyloxyphenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(4-benzyloxyphenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(3,4-dimethoxyphenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(2,4-dimethoxyphenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-naphthalen-2-ylethanone;

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts.

Claim 18. (Previously Presented) Process for the preparation of the compounds of the formula (I) according to claim 1, comprising the step consisting in using the compound of the formula (IV):



(IV)

on a halo derivative (V):

Hal-R_1 ,

in equimolar amount, in a polar solvent, at a temperature of between -20 and 200°C.

Claim 19. (Previously Presented) Process according to Claim 18, for which the said compound of the formula (IV) is prepared by addition of the corresponding derivative of the

formula (II):



(II)

in which R represents a hydrogen atom or an alkyl radical, to a 2-haloethanone derivative of the formula (III):



(III)

in which Hal represents a halogen atom, and, in a polar solvent, at a temperature of from -20 to 200°C, followed by cyclization in a polar solvent at a temperature of from -20 to 200°C.

Claim 20. (Previously Presented) Process for the preparation of the compounds of the formula (I) according to Claim 18, for which the said polar solvent is chosen from: ethanol, methanol, water, DMF, NMP, DMSO, iPrOH.

Claim 21. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ composition[[~~s~~]] comprising a compound of the formula (I):



in which:

X = O or S;

R1 is chosen from:

- Alk-COOH,

- Alk-C(=O)-$(O)_m$-Ar,
- Alk-C(=O)-$(O)_m$-Het,
- Alk-C(=O)-$(O)_m$-Alk,
- Alk-C(=O)-$(O)_m$-cycloalkyl,
- Alk-C(=O)NRR',
- Alk-$(O)_m$-Ar,
- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

R2 is chosen from -Alk, -Ar and -cycloalkyl;

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' and $-NO_2$;

in which, in the definitions of R1-R6:

each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -COOH, -NRR', -C(=O)-$(O)_m$Alk, -Het and $-NO_2$;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -AlkAr, -COOH, -C(=O)-$(O)_m$Alk, -Alk-C(=O)-$(O)_m$-Alk, -NRR', -Het, $-NO_2$, -$S(O)_n$Ar and -$S(O)_n$Alk;

R and R' are chosen independently from H and Alk;

m = 0 or 1;

or stereoisomers, ~~and also the stereoisomers thereof, the~~ racemates or ~~thereof and the~~ pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.

Claim 22. (Canceled)

Claim 23. (Currently Amended) A method for treating hyperglycaemia, comprising administering to a host in need thereof an effective amount of ~~Use of~~ a compound of

the formula (I):



in which:

X = O or S;

R1 is chosen from:

- Alk-COOH,
- Alk-C(=O)-$(O)_m$-Ar,
- Alk-C(=O)-$(O)_m$-Het,
- Alk-C(=O)-$(O)_m$-Alk,
- Alk-C(=O)-$(O)_m$-cycloalkyl,
- Alk-C(=O)NRR',
- Alk-$(O)_m$-Ar,
- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

R2 is chosen from -Alk, -Ar and -cycloalkyl;

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' and $-NO_2$;

in which, in the definitions of R1-R6:

each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -COOH, -NRR', -C(=O)-$(O)_m$Alk, -Het and $-NO_2$;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -AlkAr, -COOH, -C(=O)-$(O)_m$Alk, -Alk-C(=O)-$(O)_m$-Alk, -NRR', -Het, $-NO_2$, -$S(O)_n$Ar and -$S(O)_n$Alk;

R and R' are chosen independently from H and Alk;

m = 0 or 1,

or ~~and also the~~ stereoisomers, ~~thereof, the~~ racemates or ~~thereof and the~~ pharmaceutically acceptable salts thereof.

~~for the preparation of a medicament for reducing hyperglycaemia.~~

Claim 24. (Currently Amended) A method ~~Use of a compound of the formula (I)~~ according to Claim 23, comprising treating ~~for which the said medicament is for the treatment of~~ diabetes.

Claim 25. (Currently Amended) A method ~~Use of a compound of the formula (I)~~ according to Claim 23, comprising treating ~~for which the said medicament is for the treatment of~~ non-insulin-dependent diabetes.

Claim 26. (Currently Amended) A method ~~Use of a compound of the formula (I)~~ according to Claim 23, comprising treating ~~for which the said medicament is for the treatment of~~ dyslipidaemia and/or obesity.

Claim 27. (Currently Amended) A method ~~Use~~ according to Claim 23, comprising treating ~~for which the said medicament is for the treatment of~~ diabetes-related microvascular or ~~and~~ macrovascular complications.

Claim 28. (Currently Amended) A method ~~Use of a compound of the formula (I)~~ according to Claim 27, wherein ~~for which~~ the microvascular and macrovascular complications are ~~chosen from~~ atherosclerosis, arterial hypertension, inflammatory processes, macroangiopathy, microangiopathy, retinopathy or ~~and~~ neuropathy.

Claim 29. (Canceled)